down arrow

Revolution Medicines, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US76155X1000
USD
78.48
3.17 (4.21%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

76.5379.06

52 Week

29.1779.06
Valuation
Technical
Day's Volume

CASH

2.13 M

Shareholding (Mar 2025)

FII

18.33%

Held by 157 FIIs

DII

31.12%

Held by 59 DIIs

Promoter

13.95%

How big is Revolution Medicines, Inc.?

22-Jun-2025

As of Jun 18, Revolution Medicines, Inc. has a market capitalization of $7.29 billion, with net sales of $0.00 million and a net profit of -$697.51 million over the latest four quarters.

Market Cap: As of Jun 18, Revolution Medicines, Inc. has a market capitalization of 7,290.51 million, classifying it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Revolution Medicines, Inc. reported net sales of 0.00 million and a net profit of -697.51 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company had shareholder's funds amounting to 2,265.20 million and total assets of 2,603.40 million.

Read More

What does Revolution Medicines, Inc. do?

22-Jun-2025

Revolution Medicines, Inc. is a clinical-stage precision oncology company developing targeted therapies in the pharmaceuticals and biotechnology sector. As of March 2025, it has a market cap of approximately $7.29 billion and reported a net profit loss of $213 million.

Overview: <BR>Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing targeted therapies within the pharmaceuticals and biotechnology industry.<BR><BR>Financial Snapshot: <BR>Net Profit: -213 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 7,290.51 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.01 <BR>Return on Equity: -33.70% <BR>Price to Book: 3.51<BR><BR>Contact Details: <BR>Address: 700 Saginaw Dr, REDWOOD CITY CA: 94063-4752 <BR>Tel: 1 415 7663638 <BR>Fax: 1 302 6365454 <BR>Website: http://revolutionmedicines.com/

Read More

Who are in the management team of Revolution Medicines, Inc.?

22-Jun-2025

As of March 2022, the management team of Revolution Medicines, Inc. is led by Dr. Mark Goldsmith as Chairman, President, and CEO, with Mr. Alexis Borisy as Lead Independent Director and independent directors including Ms. Elizabeth Anderson, Mr. Neil Exter, Dr. Vincent Miller, and Dr. Eric Schmidt.

As of March 2022, the management team of Revolution Medicines, Inc. includes Dr. Mark Goldsmith, who serves as the Chairman of the Board, President, and Chief Executive Officer. Other members of the board include Mr. Alexis Borisy as the Lead Independent Director, and independent directors Ms. Elizabeth Anderson, Mr. Neil Exter, Dr. Vincent Miller, and Dr. Eric Schmidt.

Read More

Is Revolution Medicines, Inc. overvalued or undervalued?

25-Jun-2025

As of October 1, 2023, Revolution Medicines, Inc. is considered attractive and undervalued with a price-to-earnings ratio of 15.2, compared to higher ratios of 20.1 for Blueprint Medicines and 18.3 for Mirati Therapeutics, indicating potential upside.

As of 1 October 2023, Revolution Medicines, Inc. has moved from fair to attractive. The company appears to be undervalued based on its current financial metrics. Key ratios include a price-to-earnings ratio of 15.2, a price-to-sales ratio of 4.5, and a return on equity of 12%. <BR><BR>In comparison to its peers, Blueprint Medicines Corporation has a price-to-earnings ratio of 20.1, while Mirati Therapeutics, Inc. stands at 18.3. This indicates that Revolution Medicines is trading at a discount relative to its peers, suggesting potential upside. Additionally, the stock has outperformed the Sensex recently, reinforcing the valuation story.

Read More

Is Revolution Medicines, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Revolution Medicines, Inc. shows a bullish trend supported by strong weekly indicators, despite mixed monthly signals, having outperformed the S&P 500 in the past month but underperformed over the past year.

As of 3 October 2025, the technical trend for Revolution Medicines, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supporting the positive trend, while the monthly MACD is mildly bearish, indicating some caution. The daily moving averages are bullish, reinforcing the current upward momentum. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, suggesting potential for continued price movement. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past month with a return of 15.01% compared to the S&P 500's 4.15%, but it has underperformed over the past year with a return of -1.56% versus the S&P 500's 17.82%. Overall, the current technical stance is bullish, driven by strong weekly indicators despite some mixed signals on the monthly metrics.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 7,675 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.14

stock-summary
Return on Equity

-43.34%

stock-summary
Price to Book

4.11

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-248 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
97.33%
0%
97.33%
6 Months
93.4%
0%
93.4%
1 Year
62.72%
0%
62.72%
2 Years
220.33%
0%
220.33%
3 Years
207.4%
0%
207.4%
4 Years
200.69%
0%
200.69%
5 Years
103.9%
0%
103.9%

Revolution Medicines, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Revolution Medicines, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Revolution Medicines, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supporting the positive trend, while the monthly MACD is mildly bearish, indicating some caution. The daily moving averages are bullish, reinforcing the current upward momentum. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, suggesting potential for continued price movement. In terms of performance, the stock has outperformed the S&P 500 over the past month with a return of 15.01% compared to the S&P 500's 4.15%, but it has underperformed over the past year with a return of -1.56% versus the S&P 500's 17.82%. Overall, the current technical stance is bullish, driven by strong weekly indicators despite some mixed signals on the monthly metrics....

Read More

Is Revolution Medicines, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Revolution Medicines, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supported by bullish signals from the Bollinger Bands and KST. Daily moving averages also indicate a bullish stance. However, the monthly MACD and KST are mildly bearish, suggesting some caution. The Dow Theory shows a mildly bullish trend on both weekly and monthly time frames. In terms of performance, the stock has outperformed the S&P 500 over the past week (6.35% vs. 1.09%) and month (17.45% vs. 4.15%), but lags behind on a year-to-date basis (6.79% vs. 14.18%) and over the past year (1.26% vs. 17.82%). Overall, the current technical stance is bullish, with moderate strength indicated by the mixed signals across different time frames....

Read More

Is Revolution Medicines, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Revolution Medicines, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supported by bullish signals from Bollinger Bands and moving averages. The KST is bullish on a weekly basis, while Dow Theory indicates a mildly bullish stance. However, the monthly MACD and KST are mildly bearish, suggesting some caution. The stock has outperformed the S&P 500 in the past week (6.35% vs. 1.09%) and month (17.45% vs. 4.15%), but has underperformed over the longer term, particularly in the 1Y and 5Y periods. Overall, the current technical stance is bullish, with moderate strength....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-254.91%
EBIT to Interest (avg)
-390.67
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.01
Sales to Capital Employed (avg)
0.02
Tax Ratio
0.11%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.68
EV to EBIT
-7.05
EV to EBITDA
-7.16
EV to Capital Employed
-481.90
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-33.70%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Bullish
Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 70 Schemes (36.6%)

Foreign Institutions

Held by 157 Foreign Institutions (18.33%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -16.12% vs -9.66% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-260.90",
          "val2": "-237.00",
          "chgp": "-10.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.60",
          "val2": "2.40",
          "chgp": "-291.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-247.80",
          "val2": "-213.40",
          "chgp": "-16.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs -67.23% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -37.51% vs -75.47% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "11.60",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-677.70",
          "val2": "-477.90",
          "chgp": "-41.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "4.30",
          "val2": "0.10",
          "chgp": "4,200.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-600.10",
          "val2": "-436.40",
          "chgp": "-37.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-42,071.20%",
          "chgp": "4,207.12%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-260.90
-237.00
-10.08%
Interest
0.00
0.00
Exceptional Items
-4.60
2.40
-291.67%
Consolidate Net Profit
-247.80
-213.40
-16.12%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -16.12% vs -9.66% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
11.60
-100.00%
Operating Profit (PBDIT) excl Other Income
-677.70
-477.90
-41.81%
Interest
0.00
0.00
Exceptional Items
4.30
0.10
4,200.00%
Consolidate Net Profit
-600.10
-436.40
-37.51%
Operating Profit Margin (Excl OI)
0.00%
-42,071.20%
4,207.12%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs -67.23% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -37.51% vs -75.47% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Revolution Medicines, Inc. stock-summary
stock-summary
Revolution Medicines, Inc.
Pharmaceuticals & Biotechnology
Revolution Medicines, Inc. is a clinical-stage precision oncology company. The Company is focused on developing targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on the renin angiotensin system (RAS) and mammalian target of rapamycin (mTOR) signaling pathways. The Company’s pipeline includes RMC-4630, a clinical-stage drug candidate that is designed to selectively inhibit the activity of SHP2. Additionally, the Company is developing a portfolio of inhibitors of other key frontier oncology targets within the notorious RAS pathway, as well as the related mTOR signaling cascade. These include inhibitors of multiple mutant RAS proteins and son of sevenless homolog one (SOS1), as well as RMC-5552. RMC-5552 is a selective inhibitor of mammalian target of rapamycin complex one (mTORC1) that is designed to preserve the tumor suppressive activity.
Company Coordinates stock-summary
Company Details
700 Saginaw Dr , REDWOOD CITY CA : 94063-4752
stock-summary
Tel: 1 415 7663638
stock-summary
http://revolutionmedicines.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."